MTPConnect reports strong growth in Australia’s Medtech, Biotech and Pharmaceutical sector
MTPConnect – the Medical Technology, Biotechnology, and Pharmaceutical (MTP) Industry Growth Centre – has released new sector metrics that show jobs supported by the MTP sector increased by 10% to 62,000 from 2015 to 2016, and that manufacturing…
New report aims to broaden understanding of how new medicines are funded in Australia
– Stakeholders debate future of medicines funding system at launch event A new report, developed by GlaxoSmithKline Australia (GSK) and ViiV Healthcare (ViiV) will be launched as part of an initiative to raise understanding of the medicines development…
QuickFire Challenge fuels medical innovation
The Victorian Government in collaboration with Johnson & Johnson Innovation JLABS today announced the Victorian QuickFire Challenge, a competition giving healthcare entrepreneurs the chance to transform their ground-breaking research into the products that will advance the well-being of people around…
Victorian Health Minister officially opens Johnson & Johnson Innovation Partnering Office at Monash University
The new Johnson & Johnson Innovation Partnering Office at Monash (JJIPO@MONASH) was officially opened today by the Victorian Health Minister, Jill Hennessy at Monash University in Clayton. The office will serve as Johnson & Johnson Innovation’s local base…
Phosphagenics Signs a Multinational License for TPM® in Personal Care Products
Phosphagenics Signs a Multinational License for TPM® in Personal Care Products 4 December 2017, Melbourne: Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: PPGNY), is pleased to announce the signing of a non-exclusive license agreement with Rodan…
$2.5M GRANT AWARDED TO ADVANCE WOUNDVUE™ DEVELOPMENT
• Joint collaboration with University of Melbourne and Planet Innovation Adelaide, Australia, 7 December 2017: Australian medical technology company, LBT Innovations Limited (ASX:LBT) is pleased to announce it has been awarded a $2.513 million grant to advance the…
IDT Australia Executes API Development Agreement
• API Development Agreement executed with The State Government of Victoria • Total consideration over AUD 2,000,000 over the twelve month term of the project Australian pharmaceutical manufacturing and drug development company IDT Australia Limited (ASX:IDT) announces it…
Prima BioMed has just announced new clinical data from its TACTI-mel Phase I trial in Australia – which is investigating Prima’s lead drug, IMP321, in combination with KEYTRUDA in metastatic melanoma
Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima”) is pleased to announce the presentation of new data from its TACTI-mel Phase I clinical trial in Australia investigating the use of eftilagimod alpha (LAG-3Ig or IMP321), the Company’s lead…
AdAlta appoints Dr Dallas Hartman as Chief Operating Officer
AdAlta Limited (ASX: 1AD), the biotechnology company advancing its lead i-body candidate towards clinical development, is pleased to announce the appointment of experienced executive, Dr Dallas Hartman to the role of Chief Operating Officer. Dr Hartman will bring…
Patrys and Garvan Institute of Medical Research Awarded Grant
Patrys Limited (ASX: PAB), a clinical stage biotechnology company and Sydney’s Garvan Institute of Medical Research (Garvan) have recently finalized the terms of a Federal Government Innovation Connections grant to support research within the PATDX1 program. The Garvan…
New US patent for Patrys PAT-LM1
Patrys (ASX:PAB), a clinical stage biotechnology company, has been granted a US patent for its anti-cancer pre-clinical candidate PAT-LM1. The US Patent Office has issued correspondence confirming the grant of a key patent in the PAT-LM1 family, patent…
Universal Biosensors receives $7.5M under the R&D Tax Incentive
Universal Biosensors (ASX:UBI) today announced it has received $7.5M in cash under the R&D Tax Incentive for the 2016 financial year. The R&D Tax Incentive is an Australian Government program developed to assist eligible businesses recover some of…
